The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)

The Control Group received Placebo plus CDDP

Ototoxicity

Hearing Loss

The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.

Ginkgo Biloba Extract (GBE761)

The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.

Placebo

Hospital de Base do Distrito Federal (HBDF)

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-Induced Ototoxicity in Humans Beings Evaluated by Distortion Product Otoacoustic Emissions

The protective effect of GBE761 on CDDP induced ototoxicity in human beings was evaluated with DPOAE mean amplitudes and signal-to-noise ratio (SNR) values at in the frequencies ranging from 1 to 8KHz in the study and control groups, between before and after cumulative CDDP injections, in order to evaluate the significant differences in DPOAE results, and so to differentiate hearing status ( normal hearing or hearing loss) while the subjects were taking GBE or placebo.

Mirela Alves Dias

University of Brasilia

Type 2 Diabetes Mellitus

Coronary Artery Disease

Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)

Ginkgo Biloba Extract (GBE)

Taipei Veterans General Hospital

Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease

Liang-Yu, Lin/ Attending phsician

Taipei Veterans General Hospital, Taiwan

Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.

Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.

Placebo, one capsule orally twice a day for 12 weeks.

Ginkgo (EGb-761), 120-mg tablet of ginkgo twice a day for 12 weeks.

Ginkgo

Total

Sex: Female, Male

Race/Ethnicity, Customized

For each group the average number of years that participants had Multiple Sclerosis

Disease duration, average number of years

0:Normal
No disability(dis) 1.5:(min)signs
Min dis
Moderate(mod) dis
Amb no aid>=500 m 4.5:>=300 m
>=200 m 5.5:>=100 m
Amb unilateral aid>=100 m 6.5:Amb bilateral aid>=20 m
Amb < 5 m 7.5:Unable to take few steps
Bedbound, uses of arms 8.5:Bedbound some use of arms & some self care
Helpless in bed 9.5:Unable to communicate/eat/swallow
Dead

Expanded Disability Status Scale

Type of Multiple Sclerosis

Performance at exit adjusted for baseline performance on 4 neuropsychological tests:
STROOP(Victoria version):Tests attention&executive function. Outcome is the interference condition condition; time needed to name the colors in which words (which are names of colors) are printed. Words and colors are mismatched.
CaliforniaVerbalLearningTest- II: Tests verbal/learning/memory. Outcome number of words (shopping list) remembered after 20 min delay with no cues.
PacedAuditorySerialAdditionTest:Tests working memory/sustained attention. Outcome is the number of correct responses to recording giving numbers every 2 sec. Last 2 numbers must be added together before the next number.
ControlledOralWordAssociationTest:Tests letter fluency. Outcome number of words produced in one minute for each of 3 letters.
Measures reported as Z-scores based on the available population norms for each test; range -infinite +infinite; 0 average; -1=1std below average; +1=1std above average.

Ginkgo Baseline

Ginkgo Exit

Placebo Baseline

Placebo Exit

Primary Outcome is Performance on the Interference Condition of the Stroop, the Long Delay Free Recall Portion of the California Verbal Learning Test II, the 2 Second Paced Auditory Serial Addition Test and the Controlled Oral Word Association Test.

The Perceived Deficits Questionnaire (PDQ), a standardized questionnaire in which the subject reports on his or her cognitive function; Measure total score Range (0 best - 80 worse) Multiple Sclerosis Neuropsychological Screening Questionnaire (MSNQ), in which the family member who was most aware of the participant's cognitive deficits reports on the subject's cognitive deficits; measure total score range (0 best - 60 worse) 'and the Community Integration Questionnaire (CIQ) in which the subject reports his or her degree of social integration; range (0 worst - 32 best); measure total score.
Sub-scales for these 3 measures were not used for outcome measures only total scores.

Secondary Outcome: Measures of Self-report as Well as Family Reports of Subject's Cognitive Deficits and Assessment of Social Integration.

Overall Study

Dennis Bourdette, MD

Multiple Sclerosis

Cognitive Ability, General

Ginkgo biloba

One capsule orally twice a day for 12 weeks

Department of Veteran Affairs MS Centers of Excellence

Portland VA Medical Center, Portland, OR

VA Puget Sound Health Care System, Seattle

Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis

Ginkgo Biloba for Cognitive Impairment in Multiple Sclerosis

US Department of Veterans Affairs

Brain and Central Nervous System Tumors

Radiation Toxicity

EGb761

donepezil hydrochloride

cognitive assessment

CCOP - Western Regional, Arizona

Regional Radiation Oncology Center at Rome

Comprehensive Cancer Center at Wake Forest University

CCOP - Upstate Carolina

Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases

ginkgo/kræft

The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans

Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease

Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis

Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

Effects of Ginseng and Ginkgo on Drug Disposition in Man

Den mest komplette database med medicinske urter understøttet af videnskab